A Prescribing Cascade of Proton Pump Inhibitors Following Anticholinergic Medications in Older Adults With Dementia
暂无分享,去创建一个
[1] W. Peetermans,et al. Cost-effectiveness of check of medication appropriateness: methodological approach , 2022, International Journal of Clinical Pharmacy.
[2] J. Debes,et al. Assessment of proton-pump inhibitor use, race, socioeconomic status, and mortality in individuals with COVID-19. , 2021, European journal of gastroenterology & hepatology.
[3] J. Turgeon,et al. Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and Models , 2021, Drugs & Aging.
[4] E. McArthur,et al. The risk of delirium and falls or fractures with the use of overactive bladder anticholinergic medications , 2021, Neurourology and urodynamics.
[5] C. Ohyama,et al. The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan , 2021, International Urology and Nephrology.
[6] S. Hsieh,et al. Risk of Enteric Infection in Patients with Gastric Acid Supressive Drugs: A Population-Based Case-Control Study , 2021, Journal of personalized medicine.
[7] A. Ford,et al. Association of proton‐pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta‐analyses of cohort studies and randomised controlled trials , 2021, British journal of clinical pharmacology.
[8] R. Stewart,et al. Centrally Acting Anticholinergic Drugs Used for Urinary Conditions Associated with Worse Outcomes in Dementia. , 2021, Journal of the American Medical Directors Association.
[9] A. Rezapour,et al. A Systematic Review of Potentially Inappropriate Medications Use and Related Costs Among Elderly. , 2021, Value in health regional issues.
[10] T. Stürmer,et al. Effects of anticholinergic and sedative medication use on fractures: A self‐controlled design study , 2021, Journal of the American Geriatrics Society.
[11] G. Onder,et al. The Association of Anticholinergic Drugs and Delirium in Nursing Home Patients With Dementia: Results From the SHELTER Study. , 2021, Journal of the American Medical Directors Association.
[12] Umut Yener Kara,et al. Long-Term Proton Pump Inhibitor Use is a Risk Factor for Mortality in Patients Hospitalized for COVID-19. , 2021, Turkish journal of medical sciences.
[13] K. Higuchi,et al. Effect of a proton-pump inhibitor on intestinal microbiota in patients taking low-dose aspirin , 2021, European Journal of Clinical Pharmacology.
[14] E. Manias,et al. Potentially inappropriate prescribing and its associations with health‐related and system‐related outcomes in hospitalised older adults: A systematic review and meta‐analysis , 2021, British journal of clinical pharmacology.
[15] Y. Bao,et al. Anticholinergic drugs and the risk of dementia: A systematic review and meta-analysis , 2021, Neuroscience & Biobehavioral Reviews.
[16] K. Bhaskaran,et al. Proton pump inhibitors and risk of all‐cause and cause‐specific mortality: A cohort study , 2021, British journal of clinical pharmacology.
[17] L. Dolovich,et al. The Evolving Role and Impact of Integrating Pharmacists into Primary Care Teams: Experience from Ontario, Canada , 2020, Pharmacy.
[18] M. Schnitzer,et al. Trends in Prescribing Patterns of Proton Pump Inhibitors Surrounding New Guidelines. , 2020, Annals of epidemiology.
[19] H. Goyal,et al. Pre-hospitalization proton pump inhibitor use and clinical outcomes in COVID-19 , 2020, European journal of gastroenterology & hepatology.
[20] Kyungdo Han,et al. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease , 2020, BMC Geriatrics.
[21] B. Farrell,et al. Patient and provider perspectives on the development and resolution of prescribing cascades: a qualitative study , 2020, BMC Geriatrics.
[22] P. Ungprasert,et al. Use of proton pump inhibitors is associated with a higher risk of pneumonia in cirrhotic patients: a systematic review and meta-analysis , 2020, Annals of gastroenterology.
[23] T. Manini,et al. Evaluation of the Potential Acetylcholinesterase Inhibitor‐Induced Rhinorrhea Prescribing Cascade , 2020, Journal of the American Geriatrics Society.
[24] Kyungdo Han,et al. Metoclopramide and Levosulpiride Use and Subsequent Levodopa Prescription in the Korean Elderly: The Prescribing Cascade , 2019, Journal of clinical medicine.
[25] P. Burns,et al. Hospitalisation for medication misadventures among older adults with and without dementia: A 5‐year retrospective study , 2019, Australasian journal on ageing.
[26] J. Helenius,et al. Acid-suppressive medications and risk of pneumonia in acute stroke patients: A systematic review and meta-analysis , 2019, Journal of the Neurological Sciences.
[27] Wen-Chuan Lin,et al. Association of Increased Risk of Pneumonia and Using Proton Pump Inhibitors in Patients With Type II Diabetes Mellitus , 2019, Dose-response : a publication of International Hormesis Society.
[28] P. Rochon,et al. Assessing the Scope and Appropriateness of Prescribing Cascades , 2019, Journal of the American Geriatrics Society.
[29] R. Khoury,et al. Rational deprescribing in the elderly. , 2019, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.
[30] Chien-Chang Lee,et al. Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta‐analysis of randomized controlled trials and observational studies , 2019, Expert opinion on drug safety.
[31] L. Fratiglioni,et al. Risk Factors for Injurious Falls in Older Adults: The Role of Sex and Length of Follow‐Up , 2018, Journal of the American Geriatrics Society.
[32] P. Rochon,et al. What Is Known About Preventing, Detecting, and Reversing Prescribing Cascades: A Scoping Review , 2018, Journal of the American Geriatrics Society.
[33] M. Olsen,et al. An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade. , 2018, Journal of the American Pharmacists Association : JAPhA.
[34] D. Scott,et al. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors , 2017, Current Gastroenterology Reports.
[35] P. Rochon,et al. The prescribing cascade revisited , 2017, The Lancet.
[36] P. Moayyedi,et al. Deprescribing proton pump inhibitors: Evidence-based clinical practice guideline. , 2017, Canadian family physician Medecin de famille canadien.
[37] P. Moayyedi,et al. Deprescribing versus continuation of chronic proton pump inhibitor use in adults. , 2017, The Cochrane database of systematic reviews.
[38] M. Dramé,et al. Risk Factors for Adverse Drug Reactions in Older Subjects Hospitalized in a Dedicated Dementia Unit. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[39] Mohammad Rababa,et al. Proton Pump Inhibitors and the Prescribing Cascade. , 2016, Journal of gerontological nursing.
[40] P. Nishtala,et al. Anticholinergics: theoretical and clinical overview , 2016, Expert opinion on drug safety.
[41] J. Long,et al. A systematic review of the emerging definition of 'deprescribing' with network analysis: implications for future research and clinical practice. , 2015, British journal of clinical pharmacology.
[42] J. Beauchamp,et al. Proton Pump Inhibitors (PPI) , 2015 .
[43] S. Duffull,et al. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review , 2015, BMC Geriatrics.
[44] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.
[45] M. Boustani,et al. Impact of anticholinergics on the aging brain: a review and practical application , 2008 .
[46] R. McGlinchey,et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. , 2008, Archives of internal medicine.
[47] I. Forgacs,et al. Overprescribing proton pump inhibitors , 2008, BMJ : British Medical Journal.
[48] David L Streiner,et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. , 2005, Archives of internal medicine.
[49] H. Beijer,et al. Hospitalisations caused by adverse drug reactions (ADR): a meta-analysis of observational studies , 2002, Pharmacy World and Science.
[50] P. Rochon,et al. Drug therapy , 1995, The Lancet.
[51] B. Santos-Ramos,et al. Systematic review on the use of anticholinergic scales in poly pathological patients. , 2016, Archives of gerontology and geriatrics.